Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
projects in our pipeline
Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
projects in our pipeline